BioLineRx (NASDAQ:BLRX) Posts Quarterly Earnings Results

BioLineRx (NASDAQ:BLRX) issued its quarterly earnings data on Monday. The biotechnology company reported ($0.77) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.15) by ($0.62), Zacks reports. BioLineRx had a negative return on equity of 37.73% and a negative net margin of 563.70%.The firm had revenue of $0.29 million for the quarter, compared to analysts’ expectations of $0.50 million.

Here are the key takeaways from BioLineRx’s conference call:

• GLIX1 clinical trial progressing on plan: The Phase I/IIa study in glioblastoma began dosing its second of five planned cohorts, with the third expected to start in September; management reported encouraging safety and tolerability and still expects Phase I data in the first half of 2027.
• New preclinical results showed strong GLIX1 activity in glioblastoma models, including a temozolomide-resistant model, while a low-dose GLIX1–olaparib combination produced substantially better results than either monotherapy in an HR-proficient ovarian cancer model. The company plans an ovarian cancer expansion cohort and has begun discussions with PARP inhibitor developers.
• The CheMo4METPANC Phase IIb pancreatic cancer trial of motixafortide, cemiplimab and chemotherapy continues to enroll well, with an interim futility analysis expected later this year. Management acknowledged that the recent approval of a competing KRAS-targeted therapy could affect the treatment landscape but said it still sees a role for CXCR4 inhibition.
• BioLineRx ended the quarter with $13.1 million in cash, expected to fund operations into the first half of 2027, but reported a $4.3 million quarterly net loss and announced a $3.75 million registered direct offering, which adds near-term dilution risk. APHEXDA generated $1.6 million in quarterly sales and $0.3 million in royalty revenue, although adoption remains dependent on gradually changing transplant-center practices.

BioLineRx Stock Performance

NASDAQ BLRX opened at $2.80 on Tuesday. The company has a quick ratio of 1.43, a current ratio of 1.58 and a debt-to-equity ratio of 0.16. BioLineRx has a 52-week low of $2.15 and a 52-week high of $4.56. The business’s 50-day moving average price is $2.91 and its 200 day moving average price is $2.84. The firm has a market cap of $12.24 million, a P/E ratio of -1.46 and a beta of 1.54.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of BioLineRx in a research report on Friday, July 17th. One research analyst has rated the stock with a Sell rating, According to MarketBeat, the stock currently has a consensus rating of “Sell”.

BioLineRx Company Profile

BioLineRx (NASDAQ: BLRX) is a clinical-stage biopharmaceutical company that discovers and develops novel small-molecule therapies to address unmet medical needs. The company focuses on identifying promising drug candidates through licensing and collaboration agreements with academic institutions and biotech innovators, then advancing these candidates through preclinical and clinical development stages. BioLineRx’s pipeline spans oncology, immunology and inflammatory diseases, central nervous system disorders and pain management.

Among its clinical programs, BioLineRx is advancing targeted cancer therapies designed to improve outcomes for patients with difficult-to-treat tumors.